Clinical Trials Logo

Meningioma Atypical clinical trials

View clinical trials related to Meningioma Atypical.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05793034 Recruiting - Meningioma Clinical Trials

Predictive Factors for Survival in Aggressive Meningiomas

23Men
Start date: January 7, 2021
Phase: N/A
Study type: Interventional

The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.

NCT ID: NCT05259332 Recruiting - Meningioma Atypical Clinical Trials

Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas

TransMenAtyp
Start date: February 25, 2022
Phase:
Study type: Observational

Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical meningiomas. Transcriptomic study first, on cryopreserved tumor samples. Then identify, thanks to the transcriptomic study, prognostic and predictive factors (study of the link between the quantity of certain RNA transcripts and progression-free survival). Finally, set up immunohistochemical applications, which can be used routinely by the pathologist.

NCT ID: NCT05081908 Recruiting - Meningioma Atypical Clinical Trials

Multisession Radiosurgery in Residual/Recurrent Grade II Meningiomas.

ATM
Start date: May 17, 2017
Phase: N/A
Study type: Interventional

Fractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting for patients who present post-surgical residual lesion or develop recurrence.

NCT ID: NCT04792463 Recruiting - Clinical trials for Hepatocellular Carcinoma

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Start date: March 3, 2015
Phase:
Study type: Observational

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screening and earlier intervention which would improve the treatment outcome not only for retaining vision but also for overall survival. Similarly in patients with germline BAP1 mutation CM develops in premalignant atypical melanocytic lesions and careful follow up of these patients will improve the outcome of their disease. In addition this study could have impact on the management of patients with personal and/or family history of several other cancers reported in patients with germline BAP1 mutation such as mesothelioma, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, meningioma and basal cell carcinoma.